News | Blogs | Healthcare | Consulting
Contact: info@ipharmacenter.com
US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter
Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter
US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter
FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter
Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)
FDA Approved Sun Pharma's Leqselvi (deuruxolitinib) for Severe Alopecia Areata
US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer
FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease
Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter
FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio
FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma
FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter
FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer
FDA Drug Approvals | 2024 | iPharmaCenter
FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter
FDA Gives Green Light to First Medication for Individuals with Liver Scarring Stemming from Fatty Liver Condition | iPharmaCenter
2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter
FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter
Chikungunya | Drugs | Vaccines | News | Updates | iPharmaCenter
